CIK 0001540159 · Non-accelerated filer<br>Smaller reporting company
Edesa Biotech, Inc.
Sign in to watch- Ticker
- EDSA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Sep 30
- Incorporated
- British Columbia, Canada
- Entity type
- operating
- Phone
- (905) 475-1234
- Business address
- C/O FASKEN MARTINEAU DUMOULIN LLP, 333 BAY STREET, SUITE 2400, TORONTO, Ontario, Canada, M5H 2T6
- Former names
- Stellar Biotechnologies, Inc.
- SCHEDULE 13G Stake Statement of Beneficial Ownership
- UPLOAD Other SEC-generated Letter
- 3 Insider Initial Statement of Ownership
- SCHEDULE 13D Stake Beneficial Ownership Report
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- SCHEDULE 13D/A Stake Beneficial Ownership Report
- D Other Notice of Sales of Unregistered Securities
- 4 Grant or award Director acquired 10,416 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 4 Grant or award Director acquired 41,666 shares (grant or award)
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 8-K Event Material agreement · Unregistered share sale · Shareholder rights changed · Executive or director change · Bylaws or fiscal year change · Other events
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- 4 Grant or award Chief Executive Officer acquired 8,264 shares (grant or award)
- 4 Grant or award Chief Executive Officer acquired 8,476 shares (grant or award)
- 10-K/A Report 10-K/A
- 10-K Report Annual Report
- 8-K Event Results of operations
- 4 Grant or award Chief Executive Officer acquired 6,420 shares (grant or award)
Page 7 of 38 · 753 filings